[{"id":"2a12c7d5-76e8-4eae-92da-65192089b268","acronym":"","url":"https://clinicaltrials.gov/study/NCT04030195","created_at":"2022-06-24T22:54:52.342Z","updated_at":"2024-07-02T16:35:56.670Z","phase":"Phase 1/2","brief_title":"Dose-escalation Study of Safety of PBCAR20A in Subjects With r/r NHL or r/r CLL/SLL","source_id_and_acronym":"NCT04030195","lead_sponsor":"Precision BioSciences, Inc.","biomarkers":" CD20","pipe":"","alterations":" ","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • PBCAR 20A"],"overall_status":"Completed","enrollment":" Enrollment 18","initiation":"Initiation: 03/24/2020","start_date":" 03/24/2020","primary_txt":" Primary completion: 06/24/2021","primary_completion_date":" 06/24/2021","study_txt":" Completion: 06/24/2021","study_completion_date":" 06/24/2021","last_update_posted":"2023-01-31"}]